# Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

> **NCT02328755** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 37 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** peg-IFN-α
- **PROCEDURE:** Hematopoietic Cell Transplant (HCT)
- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02328755
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2019-03-25
- **Final completion:** 2019-03-25
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02328755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02328755, "Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02328755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*